Cresemba

Isavuconazonium, sold under the brand name Cresemba, is a systemic antifungal medication of the triazole class which is used to treat invasive aspergillosis and mucormycosis. It is used as the sulfate. It is taken by mouth or given via injection into a vein.

Beyond's analysis on Cresemba

• 2026-09-14 — Basilea’s partner Asahi Kasei Therapeutics starts a pediatric clinical trial in Japan for the antifungal Cresemba, widening the drug’s potential patient base

Recent news mentioning Cresemba

• 2026-09-14 — Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
• 2026-09-14 — Basileas Partner Asahi Kasei Therapeutics startet klinische Studie mit Antipilzmittel Cresemba® (Isavuconazol) bei Kindern in Japan

Appears alongside

• Japan
• Asahi Kasei Therapeutics

Browse the full archive →